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ivabradine strategy is cost-effective in both approaches in all cases at a willingness to 
pay threshold of c22,000/QALY. CONCLUSIONS: In an Austrian setting, ivabradine 
is a cost-effective treatment in stable angina patients with resting HR > 70 bpm.
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OBJECTIVES: Atrial ﬁ brillation (AF) contributes for stroke, sudden death, heart 
failure, markedly reduced exercise capacity and degraded quality of life. Therefore, 
an effective treatment of AF is expected to reduce cardiovascular (CV) events and their 
costs. In 2010, dronedarone has been approved by Korean FDA for risk reduction of 
CV hospitalization in patients who are in sinus rhythm or who will be cardioverted 
with relevant conditions. The purpose of this study is to evaluate the cost-effectiveness 
of dronedarone compared with amiodarone in Korea. METHODS: We used the 
Markov simulation model for AF patients consisting with health states for AF treat-
ment, off-AF treatment, symptomatic AF recurrences, stroke, acute coronary syn-
dromes, congestive heart failure and death. Transitional probability was obtained 
from ATHENA trial and published literatures. Patient baseline, drug cost, initiation 
and monitoring cost of AF treatment, disease state cost and adverse event cost were 
obtained from national insurance claim database. The effectiveness of amiodarone vs. 
dronedarone was drawn from results of mixed treatment comparison. Discount rate 
for cost and effectiveness were applied as 5%. From the societal perspectives, we 
evaluated cost for life-year gained (LYG) and quality adjusted life-years (QALYs) until 
patients become 100 years old. Subgroup analysis and sensitivity analysis was per-
formed to deal with uncertainty. RESULTS: In the base-case analysis, the incremental 
cost-effectiveness ratio (ICER) of dronedarone versus Amiodarone was approximately 
c2344/LYG (KRW 3.75 million, 1 Euro = 1600 KRW). Results were robust across 
subgroups. The ranges of ICER in the sensitivity analysis were from around c1875 ~ 
c3750/LYG (KRW 3 to 6 million/LYG). Fifty percent of simulations in probabilistic 
sensitivity analysis fall below a willingness-to-pay of about c3750 per QALYs (KRW 
6 million per QALYs). CONCLUSIONS: These results showed that dronedarone is 
to be cost-effective vs. amiodarone for AF patients in Korea.
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OBJECTIVES: Antihypertensive therapy is a well-established approach to reducing 
the risk of cardiovascular disease (CVD). Amlodipine besylate, a calcium channel 
blocker, has been shown to be an effective antihypertensive agent. The objective of 
this study was to evaluate the cost-effectiveness of antihypertensive therapy with 
amlodipine besylate for the prevention of CVD in Korea from a health care perspective 
over a lifetime. METHODS: To estimate long-term cost and effects, a Markov model 
consisting of nine health states was constructed: Healthy with hypertension, Angina, 
Myocardial Infarction (MI), Post-MI, Stroke, Post-stroke, CHD death, CVD death, 
non-CVD cause death. One health state to another can occur with a certain probability 
at yearly intervals. The incidence of CVD was obtained from published local sources, 
whereas the risk reductions associated with antihypertensive therapy were taken from 
the medical literature, selected studies randomly assigned amlodipine besylate or 
placebo and followed up for at least 1 year. Utility values for CVD and costs of 
amlodipine besylate were drawn from published literature based on 2005 Korea 
National Health and Nutritional Examination Survey (KNHANES) data, and Korean 
pharmaceutical pricing lists, respectively. Costs for CVD were found in published 
cost-of-illness studies based on local hospital charge data. Patient outcomes were 
modeled for 45 years, and incremental cost-effectiveness ratios were calculated for 
amlodipine besylate compared with placebo. RESULTS: For a 55-year-old patient 
with hypertension, the incremental cost of amlodipine besylate compared with placebo 
was 3,213,660 Korean won (KW) per patient, although the incremental effectiveness 
of amlodipine besylate was 0.210 quality-adjusted life-years (QALYs) gained per 
patient. Therefore, the incremental cost-effectiveness ratios associated with amlodipine 
besylate were 15,288,941 KW/QALY, compared to no treatment. Sensitivity analyses 
indicated these results to be robust. CONCLUSIONS: The results from the model 
indicate that amlodipine besylate provides a cost-effective antihypertensive treatment 
strategy for the prevention of CVD in Korea.
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OBJECTIVES: The currently recommended standard treatment of the venous throm-
boembolism (VTE) are the oral anticoagulants (OA) in the majority of patients and 
the low-molecular-weight heparins (LMWH) in the selected subpopulations. The 
titration of the OA doses is difﬁ cult and often ineffective. The goal of this research 
was to compare the OA and the LMWH in the VTE treatment in terms of effectiveness, 
safety and cost-effectiveness. METHODS: The systematic review of the scientiﬁ c lit-
erature comparing the VTE treatment with OA and LMWH was performed. Among 
others, the resources of the Cochrane Library, the MEDLINE, the Embase and the 
Biomed Central were searched. The metaanalysis of the reported treatment outcomes 
was performed using the RevMan5® software. The cost analysis and the cost-effec-
tiveness analysis were performed. The data on the costs of treatment of the VTE in 
Poland were collected through the retrospective review of patient records obtained 
from the three hospitals and the anticoagulation clinic in the Krakow area, the phar-
maceutical reimbursement databases and the public payer’s charge tariffs for the 
medical services. The modeling (decision tree) was performed using the TreeAge-
Pro2009® software. RESULTS: The most important differences between the OA and 
the LMWH were related to the better prevention of the VTE incidence and the better 
prevention of the small bleedings. With respect to none of the assessed outcomes the 
OA were better than the LMWH. Within a six month treatment period the Incremental 
Cost-Effectiveness Ratio of avoiding the complication incidents was 49,865 zlotys 
(c12,242) from the payer perspective and 3,609 zlotys (c887) from the patient perspec-
tive. CONCLUSIONS: The LMWH offer the better effectiveness and safety than the 
OA but their cost-effectiveness is still limited by the relatively high prices of the 
LMWH.
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OBJECTIVES: Despite the continuing interest in health economic research, we could 
ﬁ nd no comprehensive and accessible data set on costs and effects, useful as practical 
information for decision makers who must allocate scarce resources within the car-
diovascular ﬁ eld. The objective of this study was to present the cost-effectiveness 
league table, used in the Swedish national guidelines for heart disease and highlight 
issues of importance when communicating and interpreting cost-effectiveness evidence 
to decision makers. METHODS: A unique systematic literature search for the treat-
ment of heart diseases was conducted. We then compiled all available cost-effective-
ness ratios for different heart conditions and treatment strategies, in a so called league 
table. All cost-effectiveness results were expressed as a cost per quality adjusted life-
years (QALY) or life-year gained. The league table was broken down to illustrate how 
health economic results may be communicated and made accessible to decision 
makers. We have highlighted methodological issues when interpreting cost-effective-
ness league tables by using implantable cardioverter deﬁ brillators (ICDs) as an 
example. RESULTS: More than 200 cost-effectiveness ratios were found and compiled 
in the league table ranging from dominant to c950,000 per QALY. Using ICD as an 
example we identiﬁ ed various problems when interpreting league table results. The 
results are context speciﬁ c, time dependant, comparator dependent, often based on 
point-estimates giving a false sense of precision. CONCLUSIONS: League tables 
provide a means of presenting cost-effectiveness evidence aiding decision makers with 
valid information within a limited space. We have given examples and presented ways 
of communicating cost-effectiveness results for e.g. target groups, focusing on how 
information included in a cost-effectiveness league table may be interpreted and 
conveyed and used as a tool in the decision-making process.
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OBJECTIVES: The UK’s National Institute for Health and Clinical Excellence (NICE) 
and the Jordan ofﬁ ce of the Medicines Transparency Alliance embarked on a pilot 
project to design an evidence-based guideline for cost-effective pharmacological treat-
ment of essential hypertension in Jordan. The project’s objectives were to directly 
address a major health problem for Jordan by producing a guideline; and to delineate 
the strengths and weaknesses of Jordan’s health care process to allow similar future 
efforts to be planned more efﬁ ciently. METHODS: The pilot spanned a period of 
approximately 8 months. Activities were overseen by local technical and guideline 
development teams, as well as experts from NICE. NICE’s hypertension guidelines 
and economic model were used as a starting point. Parameters in the economic model 
were adjusted according to input and feedback from local experts with regards to 
Jordanian physician and patient practices, resource costs, and quality of life estimates. 
The results of the economic model were integrated with the updated available clinical 
trial literature. RESULTS: The outputs of the economic model were used to inform 
recommendations, in the form of a clinical algorithm. a report of the process and the 
strengths and weaknesses observed was developed, and recommendations for improve-
ments made. CONCLUSIONS: The pilot represented the start of what is intended to 
be a health care process change for the country of Jordan. Issues emerged which can 
inform strategies to ensure a more cohesive and comprehensive health care approach 
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to the cost-effective use of appropriate drugs in managing chronic disease. The project 
highlighted how countries with relevant experience in evidence-informed policy 
making in health care can assist others in strengthening their decision-making systems.
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OBJECTIVES: The aim of this study was to evaluate costs and beneﬁ ts of diagnosing 
patients with syncope of unknown aetiology with implanted loop recorders compared 
to clinical practice (conventional investigation) of an electrophysiology, from the 
Spanish National Health System perspective. METHODS: Based on an economic 
decision analysis model, the cost-effectiveness study analyses diagnostic yield results 
from clinical practice versus Reveal DX®, with a time horizon of one year. Clinical 
data and resource use was obtained from a randomised controlled trial and expert 
opinion. Cost data was expressed in Euros 2010. a univariate sensitivity analysis was 
carried out to analyze the robustness of the model by modifying the number of out-
patient visits, the costs and the diagnostic yield for both strategies. RESULTS: The 
incremental cost-effectiveness Ratio of Reveal DX® versus conventional investigation 
was c3167 per additional diagnosis, resulting in a conﬁ dence interval of 95% of the 
incremental cost-effectiveness ratio of c2335–c4867 per additional diagnosis made. 
The results of the univariate sensitivity analyses did not change the main results from 
our study. CONCLUSIONS: Reveal DX® in the diagnosis of syncope of unknown 
aetiology after an initial evaluation is a cost-effective strategy compared to conven-
tional diagnosis for the Spanish Health System, since it increases diagnostic yield at a 
reasonable incremental cost.
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OBJECTIVES: In patients with acute coronary syndrome (ACS) undergoing percuta-
neous coronary intervention (PCI), the TRITON-TIMI 38 trial (TT38) demonstrated 
that treatment with prasugrel vs. clopidogrel was associated with signiﬁ cantly reduced 
rates of atherothrombotic events, though with increased risk of bleeding. The aim of 
the analysis was to evaluate the long-term cost-effectiveness of a 12-month treatment 
with prasugrel vs. clopidogrel in the trial population, excluding patients with prior 
transient ischemic attack or stroke, from the perspective of the Spanish health care 
system. METHODS: A Markov model was developed based on risk equations for 
cardiovascular death, myocardial infarction (MI) or stroke, bleeding, and rehospital-
ization, derived from TT38 data (N = 13,608 patients). Cost variables included were 
medication and hospitalizations costs. Hospital readmissions captured during TT38 
in all patients from 8 countries (N = 6705) were assigned to Spanish diagnosis related 
groups, and were modelled to accrue over the life-time horizon. Long term survival 
and quality adjusted survival were estimated for the life-time of each patient. 
RESULTS: At 12 months, a difference in drug costs between prasugrel and clopidogrel 
of +c77 (branded clopidogrel) to +c460 (generic clopidogrel) per patient was partially 
offset by hospital cost savings (−c97 per patient) due principally to reduced rates of 
revascularization. In the longer-term, prasugrel was associated with higher total costs 
(+c11 to +c395 per patient), life expectancy gains of 0.07 years, due primarily to the 
reduced rate of MI, and 0.05 additional QALYs, resulting in incremental costs per 
life-year saved and per QALY gained of c164 to c5718 and c216 to c7540, respec-
tively. Probabilistic sensitivity analysis indicated that prasugrel has a 68% to 72% 
probability of being more cost-effective than clopidogrel at a willingness to pay of 
c30,000 per QALY. CONCLUSIONS: Among ACS-PCI patients, these results showed 
prasugrel to be within the bounds of reasonable cost-effectiveness for Spain in com-
parison with clopidogrel.
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OBJECTIVES: Atrial Fibrillation (AF) is a common cardiac arrhythmia and a signiﬁ -
cant cause of morbidity and mortality worldwide. As it is necessary to maximize value 
from the money spent in health care, an economic evaluation was undertaken to 
compare a new therapy, Dronedarone, in relation to Amiodarone, Sotalol and 
Propafenone already used in the Greek National Health Service (NHS) setting. 
METHODS: An international Markov model was locally adapted. The model reﬂ ects 
the management and the progression of AF patients through different health states in 
the course of their life time, including stroke, post stroke, heart failure (HF), post-HF, 
acute coronary symptom (ACS) post-ACS and death. Clinical and quality of life data 
to populate the model were derived from a variety of relevant clinical studies and 
registries including: ATHENA, AFTER, DIONYSOS, AFFIRM and synthesizing 
analyses undertaken by academic experts. Resource utilization and cost data were 
derived by means of a large and representative panel of local experts, who utilized 
patient data ﬁ les and data which came from a sample of NHS hospitals. Data refer 
to the year 2010 and all outcomes were discounted at a rate of 3.5%. The model is 
probabilistic to account for uncertainly and mean estimates are reported with corre-
sponding uncertainty intervals. RESULTS: Mean total treatment costs were: Droneda-
rone: c12,931 (95%UI: 12,065–c12,495); Amiodarone: c8893 (95%UI: c8685–c9100); 
Sotalol: c6,185 (95%UI: c5901–c6509); Propafenone: c8433 (95%UI: c8229–c8642). 
The incremental cost-per-life-year-gained with Dronedarone versus Amiodarone was: 
c2236 (95%UI: 1897–c2615), versus Sotalol: c2576 (95%UI: c2442–c2822 and 
versus Propafenone: c2718 (95%UI: c2497–c3395). The incremental cost-per-quality-
adjusted-life-year gained with Dronedarone versus Amiodarone was: c3275 (95%UI: 
2730–c3838), versus Sotalol: c4319 (95%UI: c4130–c4510) and versus Propafenone: 
c3138 (95%UI: c2571–c4004). CONCLUSIONS: The newly available treatment 
Dronedarone appears to be a cost-effective alternative to other already existing thera-
pies, used in the management of Atrial Fibrillation patients in the Greek NHS.
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OBJECTIVES: Aortic Stenosis (AS) is a severe cardiovascular condition the treatment 
of which often involves a major operation. For a subgroup of patients medical manage-
ment (MM) is the only treatment option due to procedural risk. a transcatheter aortic 
valve implantation device “CoreValve,” is a novel procedure, is less invasive and 
allows for the implantation of a replacement valve in this patient group. Since informa-
tion is not yet available on key clinical parameters, we modiﬁ ed an existing early stage 
economic model to perform a value of information (VoI) analysis to informing the 
prioritization of future research. METHODS: The underlying model used in the 
analysis is a 10-year Markov model was developed in Microsoft Excel. Treatment 
options were CoreValve and MM with parameters derived from published literature. 
All costs were taken from the most recent published sources. Decrements were applied 
to age-speciﬁ c EQ-5D population norms to generate QALYs. a probabilistic sensitivity 
was used to inform the global Expected Value of Perfect Information (EVPI) calcula-
tion. Deterministic one way analyses were used to select the variable groups and 
individual parameters on which partial EVPI (EVPPI) calculations were performed. 
Annual incident population estimates were derived from information in a large 
national database. RESULTS: Assuming a decision horizon of 10 years, an annual 
incident population of 4052 and a willingness to pay threshold of £30,000 per QALY 
gained the EVPI is £11.3 million. EVPPI estimates were generated for costs, utilities, 
overall survival (MM patients) and treatment effects. Of these, the VoI for baseline 
mortality and long term mortality reduction were greatest (£21,364,000 and 
£8,151,000 respectively). The VoI for all others was negligible CONCLUSIONS: 
Further information on long term survival would have the greatest impact on decision 
uncertainty. Thus, a new clinical trial may not be required and a registry may be more 
appropriate.
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OBJECTIVES: To evaluate the cost-effectiveness of dronedarone for the treatment of 
atrial ﬁ brillation (AF) compared to current antiarrhythmic drugs (AADs), from a UK 
NHS perspective. METHODS: A cost-utility analysis was performed, for which an 
individual patient lifetime discrete event simulation model was constructed. The model 
predicted a patient’s course for a treatment pathway based on the current National 
Institute for Health and Clinical Excellence (NICE) AF guidelines and compared treat-
ment with amiodarone, sotalol and Class 1c agents to dronedarone. The model consisted 
of seven AF-related events; AF recurrence, acute coronary syndromes, stroke, congestive 
heart failure, treatment discontinuation, AF status change and mortality. Between events 
patients resided in four health states; normal sinus rhythm, permanent AF with uncon-
trolled symptoms, permanent AF with controlled symptoms and death. Patient’s baseline 
event risks were estimated from the non-active comparator arm of the ATHENA trial 
then adjusted for treatment effects based on a mixed treatment comparison. Cost data 
were elicited from existing literature and UK reference costs. Quality of life estimates 
were based on data from the AFTER cohort. Cost-effectiveness was measured in cost 
per quality adjusted life-year (QALY) gained. Costs and QALYs were discounted at 
3.5%. One-way and probabilistic sensitivity analyses (PSA) were performed. RESULTS: 
Dronedarone was shown to be cost-effective with incremental cost-effectiveness ratios 
of £2,406 versus amiodarone, £1,911 versus sotalol and £18,737 versus Class 1c 
agents. One-way sensitivity analysis showed that treatment effect on mortality was 
the key driver of cost-effectiveness. PSA results estimated that dronedarone was cost-
effective at an acceptability threshold of £20,000 on 95% of occasions compared to 
amiodarone and sotalol and on 60% of occasions compared to Class 1c agents. 
CONCLUSIONS: The results of this analysis demonstrate that in the UK setting 
dronedarone is a cost-effective treatment of AF compared to current AAD 
treatment.
